Journal
PSYCHIATRY RESEARCH-NEUROIMAGING
Volume 194, Issue 1, Pages 79-84Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.pscychresns.2011.03.004
Keywords
Basal ganglia; Outcome; Negative; Longitudinal
Categories
Funding
- Premi Fi de Residencia Hospital Clinic
- Fundacion Espanola de Psiquiatria
- Government of Catalonia, Comissionat per Universitats I Recerca del Departament d'Innovacio, Universitats I Empresa (DIUE) [2009SGR1295]
- Fondo de Investigacion Sanitaria of the Ministerio de Ciencia e Innovacion [PI080055]
- Janssen-Cilag
- GlaxoSmithKline
- CIBERSAM
- Generalitat de Catalunya (DIUE)
- Ministerio de Ciencia e Innovacion (FIS, ISCIII), IDIBAPS
- Fundacion Espanola de Psiquiatria Salud Mental
Ask authors/readers for more resources
Alterations in the dopaminergic system have long been implicated in schizophrenia. A key component in dopaminergic neurotransmission is the striatal dopamine transporter (DAT). To date, there have been no longitudinal studies evaluating the course of DAT in schizophrenia. A 4-year follow-up study was therefore conducted in which single photon emission computed tomography was used to measure DAT binding in 14 patients and 7 controls. We compared the difference over time in [I-123]FP-CIT striatal/occipital uptake ratios (SOUR) between patients and controls and the relationship between this difference and both symptomatology and functional outcome at follow-up. We also calculated the relationship between baseline SOUR, symptoms and functional outcome at follow-up. There were no statistically significant differences between patients' SOUR changes over time and those of controls. A significant negative correlation was observed between patients' SOUR changes over time and negative symptomatology at follow-up. A significant negative correlation was also found between baseline SOUR in patients and negative symptomatology, and there was a significant association between lower SOUR at baseline and poor outcome. Although the study found no overall differences in DAT binding during follow-up between schizophrenia patients and controls, it demonstrated that differences in DAT binding relate to patients' characteristics at follow-up. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available